| Literature DB >> 23304674 |
Biyan Wang1, Jinliang Xie, Pengqian Fang.
Abstract
BACKGROUND: In order to provide guidance on the efficient allocation of health resources when handling public health emergencies in the future, the study evaluated the H1N1 influenza prevention and control program in Hubei Province of China using cost-benefit analysis.Entities:
Keywords: Cost-benefit; H1N1 influenza; Prevention and control
Year: 2012 PMID: 23304674 PMCID: PMC3521884
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
The direct and indirect treatment costs for diagnosed patients
| The direct treatment costs | — | 8,423,400 |
| Inpatient cases | 6416.16 | 4,876,300 |
| Outpatient cases | 1652.11 | 3,547,100 |
| Indirect treatment costs | — | 3,910,200 |
| Inpatient cases | 4790.80 | 3,641,000 |
| Outpatient cases | 125.40 | 269,200 |
| Total | — | 12,333,600 |
The costs of medical observation for patients clinically diagnosed at home
| Inspection | 152 | 400,500 |
| Drugs | 58 | 152,800 |
| Disinfectants | 108 | 284,600 |
| Others | 150 | 395,300 |
| Total | 468 | 1,233,200 |
Costs of isolated observation for close contacts
| Isolation in hotel | 528 | 5,477.42 | 2,890,000 |
| Isolation in hospital | 1623 | 3,737.84 | 6,067,800 |
| Isolation at home | 344 | 210.00 | 72,200 |
| Total | — | — | 9,030,000 |
The costs of detection for H1N1 influenza cases
| Specimen collection | 9,702 | 20 | 194,000 |
| Virus isolation and identification | 3,956 | 180 | 712,100 |
| Nucleic acid detection | 7,982 | 400 | 3,192,800 |
| Serology tests | 422 | 50 | 21,100 |
| Total | — | — | 4,120,000 |
The total costs for H1N1 influenza prevention and control in Hubei
| Direct and indirect cost of treatment for diagnosed patients | _ | 12,334 | 4.65 |
| Medical observation for clinically diagnosed patients at home | 468.00 | 1,233 | 0.47 |
| Isolated observation for close contacts | _ | 9,030 | 3.41 |
| Detection for influenza cases | _ | 4,120 | 1.55 |
| Influenza surveillance network laboratories | 106.29 | 14,880 | 5.61 |
| Vaccine purchase and vaccination | 26.25 | 118,140 | 44.57 |
| Other costs besides vaccine allocated by Hubei Finance | _ | 15,630 | 5.90 |
| Other costs allocated by local Finance | _ | 70,000 | 26.41 |
| Costs of other associated units | _ | 19,720 | 7.44 |
| Total | _ | 265,087 | 100 |
The direct benefit of H1N1 prevention and control in Hubei in 2009
| Laboratory-confirmed cases | 52.45 | 70,362 | — | 298,496.9 |
| including : inpatients | 13.71 | 18,392 | 11,206.96 | 206,119.6 |
| outpatients | 38.74 | 51,970 | 1,777.51 | 92,377.4 |
| Clinically diagnosed cases | 47.55 | 63,789 | 468.00 | 29,853.2 |
| Total | 100 | 134151 | — | 328,350.1 |
Outcome of indirect benefit
| The avoided economic burden of death | 642,988.1 | 60.48 |
| The avoided work-delay for patients and families | 348,792.6 | 32.81 |
| The avoided loss of hospitals’ income | 61,546.8 | 5.79 |
| Other avoided losses | 9,782.0 | 0.92 |
| Total | 1,063,109.5 | 100 |
Outcome of total benefit
| Direct benefit | 328,350.1 | 23.60 |
| Indirect benefit | 1,063,109.5 | 76.40 |
| Total | 1,391,459.6 | 100 |